Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
Hugo Ford(Cambridge University Hospitals NHS Foundation Trust), Janet Dunn(National Health Service), Jonathan Wadsley(Weston Park Cancer Centre), Srinivasan Madhusudan(University of Nottingham), Ian Chau(Royal Marsden NHS Foundation Trust), D. Fyfe(Royal Lancaster Infirmary), Gary Middleton(University Hospitals Birmingham NHS Foundation Trust), Andrea Marshall(Coventry (United Kingdom)), David Cunningham(Royal Marsden NHS Foundation Trust), Jane Blazeby(University Hospitals Bristol NHS Foundation Trust), Natalie Cook(The Christie NHS Foundation Trust), Tobias Janowitz(Northwell Health), Daniel Swinson(St James's University Hospital), Wasat Mansoor(The Christie NHS Foundation Trust), John Bridgewater(University College London Hospitals NHS Foundation Trust), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), Paula Kareclas(Cambridge University Hospitals NHS Foundation Trust), Stephen Falk(At Bristol)
Cited by 604
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k